NCT01178762|CompletedResultsDMC
Loading search results
Sponsor study identifier
interventional
42
1 country
1
Study Start
September 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2007
Actual (reported)Study Completion
December 2007
Actual (reported)Chlamydia trachomatis is one of the major causes of sexually transmitted disease and also the leading infectious cause of blindness in the world.Treatment of C. trachomatis eye infection has involved for a long time. The efficacy of single dose azithromycin has already been demonstrated as effective in the treatment of both trachoma and adult inclusion conjunctivitis.However, in our clinical experience, some patients of chlamydial conjunctivitis may require augmented single dose azithromycin treatments before C. trachomatis is eradicated. In this way, we would like to known the efficacy of single dose and augmented single dose azithromycin in the treatment of chlamydial conjunctivitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2007
Date type not reportedThis date has not been verified as actual or estimated.
November 2007
Actual (reported)December 2007
Actual (reported)August 31, 2008
Actual (reported)August 10, 2010
Actual (reported)October 27, 2010
Actual (reported)Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments
We performed direct fluorescent antibody (DFA) tests for Chlamydia by swabbing across the lower and upper tarsal conjunctiva four times after topical application of 0.5% proparacaine. All of the DFA tests were examined by the same experienced microbiologist who was masked to the identities and clinical conditions of the patients. Each DFA slide was read under a fluorescent microscope and was observed for discrete fluorescent chlamydial elementary bodies (EBs).The DFA test was considered positive if above 10 EBs were counted per high-power field.
4 weeks, 8 weeks and 12 weeks after the first dose of the medication
Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
National Taiwan University Hospital
Taipei, 100, Taiwan
Yu-Chih Hou, MD
National Taiwan University Hospital
Fung-Rong Hu, MD
National Taiwan University Hospital
Yan-Ming Chen, MD
National Taiwan University Hospital
42 participants (actual enrollment reported by the registry).
First Submitted
August 31, 2008
First Posted
August 10, 2010
Study Start
September 2007
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
November 2007
Actual (reported)Study Completion
December 2007
Actual (reported)Last Updated
October 27, 2010
Results First Posted
October 27, 2010
Record last verified: 2010-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: